▲March 19-20The 11th Chengdu BiomedicalInnovators Summit
Scan to register
Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Please feel free to leave comments pointing them out. This article is only an introduction to drugs related to healthcare.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。
--Sales growth of 9.1% reported in Q4 2025, reaching $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%; Q4 earnings per share (EPS) at $2.10, adjusted EPS at $2.46, both figures impacted by ($0.10) due to the acquisition of Halda Therapeutics.--Full-year 2025 reported sales growth of 6.0%, reaching $94.2 billion, operational growth of 5.3%, and adjusted operational growth of 4.2%; full-year earnings per share of $11.03, adjusted earnings per share of $10.79, both figures impacted by ($0.10) due to the acquisition of Halda Therapeutics.-- Major annual innovative achievements include: CAPLYTA approved for the treatment of major depressive disorder; RYBREVANT FASPRO in combination with LAZCLUZE approved for the treatment of non-small cell lung cancer; milestone data for TECVAYLI in combination with DARZALEX FASPRO in the treatment of relapsed/refractory multiple myeloma, indicating its potential to become the new standard for second-line treatment; completion of the acquisition of Halda Therapeutics; OTTAVA robotic surgical system submitted for approval.-- The company issued its 2026 earnings guidance: reported sales are expected to reach $100.5 billion (midpoint increase of 6.7%), and adjusted earnings per share are projected to be $11.53 (midpoint increase of 6.9%).
Copyright statement: This article is reproduced from Huachuang Pharmaceuticals, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
